Engineered immune cells take aim at tough lung cancer
NCT ID NCT05680922
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called LB2102, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack DLL3, a protein found on certain lung cancer cells. The study includes about 41 adults with advanced small cell lung cancer or large cell neuroendocrine lung cancer who have already tried standard treatments. The main goal is to find a safe dose and check for side effects, while also seeing if the treatment can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10017, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Kentucky - Markey Cancer Center
Lexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lung cancer
- Immunotherapy combo targets rare, aggressive lung cancer
- New writing therapy aims to ease fear in advanced cancer patients
- New drug combo aims to outperform standard care in aggressive lung cancer
- New drug cocktail aims to tame rare lung cancer
- New cocktail of drugs shows promise for tough lung cancer